BC Cancer Foundation

Recent papers from BC Cancer Foundation

1. IARC Perspective on Lung Cancer ScreeningNew England Journal of Medicine · 2026
2. 66 Relationship Between Health-related Quality of Life and Efficacy in the Phase 3 LITESPARK-005 Study of Belzutifan versus Everolimus in Previously Treated Advanced Clear Cell Renal Cell CarcinomaThe Oncologist · 2026
3. Lupus Double-Negative B Cells Harbor Expanded Somatic Mutations in Lymphoma-Relevant PathwaysThe Journal of Rheumatology · 2026
4. Germline CDK12 variants in aggressive prostate cancerCancer Discovery · 2026
5. Development and characterization of a novel, small animal external beam irradiator using a clinical high dose rate brachytherapy sourceMedical Physics · 2026
6. Brigimadlin Versus Doxorubicin in Advanced Dedifferentiated Liposarcoma: Efficacy, Safety and Translational Data from Brightline-1, a Randomized Phase 2/3 TrialClinical Cancer Research · 2026
7. Phase 1b trial of Bavdegalutamide (ARV-110) in combination with Abiraterone for metastatic prostate cancerClinical Cancer Research · 2026
8. C16-09 Quantifying the Long-term Impact of US Tobacco Control on COPD Burden: Results From the COPD-Natural History ModelAmerican Journal of Respiratory and Critical Care Medicine · 2026
9. B97-09 Impact of Aeroallergens and Woodsmoke on Differentiated Airway Epithelial CellsAmerican Journal of Respiratory and Critical Care Medicine · 2026
10. Impact of Surgical Margins in Chest Wall Chondrosarcomas: A CanSaRCC StudyJournal of Surgical Oncology · 2026
11. SPEN loss drives extra-follicular diffuse large B cell lymphoma with female-specific lethality and therapeutic vulnerabilitiesCancer Discovery · 2026
12. IL1RAP antibody-drug conjugates potently target primary and metastatic disease in multiple oncofusion-driven cancersCancer Discovery · 2026
13. RC48G001: A phase 2 study of disitamab vedotin in HER2-expressing previously treated advanced UC.Journal of Clinical Oncology · 2026
14. FORAGER-2: A randomized phase 3 study evaluating the efficacy and safety of vepugratinib combined with enfortumab vedotin and pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma with an FGFR3 genetic alteration.Journal of Clinical Oncology · 2026
15. Development of a pharmacist-led drug interaction assessment service for patients with cancer diagnosed with mild to moderate COVID-19 infection requiring outpatient treatmentJournal of Oncology Pharmacy Practice · 2026
16. Development of an Optimized CXCR4-Targeting Theranostic PairJournal of Nuclear Medicine · 2026
17. Effects of a structured exercise program on motivational outcomes in patients with Colon cancerJNCI Journal of the National Cancer Institute · 2026
18. Economic evaluation of multiple falls prevention interventions among community-residing older adults: we know the ‘value’, but what about ‘value for money’?Age and Ageing · 2025
19. Patient and population impacts of multigene panel and pembrolizumab coverage in metastatic melanomaJNCI Journal of the National Cancer Institute · 2025
20. Personalizing lung cancer screening recommendations for heterogeneous populations: a microsimulation studyJNCI Journal of the National Cancer Institute · 2025